Demystifying Medicine Video

Novel cancer treatments are at the forefront of current nuclear research. One such therapy, known as targeted internal radiation therapy, uses radioactive molecules that can target and bind to the surface of cancer cells, destroying their DNA and killing them. This provides an alternative to chemotherapy and radiation therapy which apply toxic doses to the entire body, thereby killing cancer cells but also good cells, compromising patient immunity. Many of these exciting advancements are in clinical trials and are awaiting Health Canada approval.

[Please complete our feedback form]

Author Details


  • Armstrong, A., (2020, March 24). Radioisotopes in Medicine McMaster University [PowerPoint slides] Internal radiation therapy - Canadian Cancer Society. (n.d.). Retrieved September 27, 2020, from
  • Kratochwil, C., Giesel, F. L., Stefanova, M., Bene Ova, M., Bronzel, M., Afshar-Oromieh, A.,.. Haberkorn, U. (2016). PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Journal of Nuclear Medicine, 57(8), 1170-1176. doi:10.2967/jnumed.115.171397
  • National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine. Advancing Nuclear Medicine Through Innovation. Washington (DC): National Academies Press (US); 2007. 4, Targeted Radionuclide Therapy. Available from:
  • Side effects of chemotherapy - Canadian Cancer Society. (n.d.). Retrieved September 27, 2020, from
  • Survival statistics for prostate cancer - Canadian Cancer Society. (n.d.). Retrieved September 27, 2020, from

Accessibility for Ontarians With Disabilities Act (AODA)


The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at